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ABSTRACT It has been established in the recent several decades that stem cells play a crucial role in tissue re-
newal and regeneration. Mesenchymal stem cells (MSCs) are part of the most important population of adult stem 
cells. These cells have hereby been identified for the very first time and subsequently isolated from  bone marrow 
stroma. Bone marrow-derived MSCs have been believed to play the role of a source of cells for the renewal and 
repair of connective tissues, including bone, cartilage and adipose tissues.  Cells similar to bone marrow-derived 
MSCs have now been identified in all postnatal tissues.  Data on the distribution and function of MSCs in vivo 
collected using novel approaches pertaining to the identification of MSCs in situ, to their isolation from tissues, 
and finally to the determination of their biological properties have enabled  successful revision of the role of 
MSCs in various organs and tissues. This review summarizes our own, as well as others’, data concerning the role 
of MSCs in the regulation processes of tissue repair and regeneration. In our opinion, MSCs provide the connec-
tion between the blood-vascular, immune, endocrine, and nervous systems and tissue-specific stem cells in the 
body.
KEYWORDS mesenchymal stem cells; tissue regeneration; differentiation; cell therapy.
ABBREVIATIONS HSC – hematopoietic stem cell; MSC – mesenchymal stem cell; MMSC –multipotent mesenchy-
mal stromal cell; TSC – tissue-specific stem cell.
t
he conception of tissue renewal being facilitated 
by a self-sustaining pool of stem cells was first 
formulated in the study of hematosis over a 
century ago [1]. However, the existence of hematopoi-
etic stem cells (HScs) from which  all blood cell types 
stem was confirmed experimentally only in the mid-
dle of the 20th century [2]. until then, it was believed 
that the cellular composition of postnatal tissues was 
replenished as a result of the division of specific (dif-
ferentiated) cells. the concept that the renewal  occurrs 
as a result of the activity of stem cells was considered   
a mechanism limited  only to blood cells; a unique, 
rapidly renewing tissue containing a great number of 
functionally heterogeneous cell types. It has now been 
proven  that the maintenance and replenishment of the 
cellular composition in almost all tissues of the human 
body (including skin and intestinal epithelium, liver, 
skeletal muscles, and myocardium) occur through the 
proliferation and differentiation of the corresponding 
tissue-specific stem cells (tScs). However, along with 
the tissue-specific stem cells,  other stem cells, known 
as mesenchymal stem cells (MScs), have been identi-
fied in mammalian tissues.
the first body of data indicating the presence of 
postnatal stem cells, along with hematopoietic stem 
cells, in  bone marrow was obtained by means of sev-
eral approaches. the first indication was the occur-
rence of osteogenesis in  experimental models following 
the intraperitoneal transplantation of cultivated bone 
marrow stromal cells [3]. the second indication was 
the isolation of a cell population from the bone marrow 
that differs from hematopoietic stem cells but exhib-
its  properties typical of stem cells. During cultivation, 
these cells  cloned (the colonies of fibroblast) [4], main-
taining their ability to differentiate into a variety of cell 
types (osteoblasts, adipocytes, and chondrocyte) [5].
the assumption was, by  analogy with HScs, that   
bone marrow-derived MScs were at the top of the 
mesenchymal hierarchy [6, 7] (Fig. 1). It was suggest-
ed that, throughout life,  descendants of these cells 
undergo several discrete stages of differentiation, 
thereby spawning the various cells found in connec-
tive tissues, i. e.: in bone and adipose tissues, tendons, 
cartilages, and smooth muscles [8]. Later, the cells with 
phenotypic characteristics and differentiation potential 
similar to bone marrow-derived MScs were isolated 
from almost all the embryonal and postnatal tissues of 
mammals, birds, and amphibians [9, 10]. On the basis 
of these observations, a theory emerged, postulating 
that bone marrow is a deposit of both hematopoietic 
and mesenchymal stem cells. However, the suggestion 
that the renewal of connective tissues over the whole reVIeWS
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body depends on the activity of bone marrow-derived 
MScs as yet remains unconfirmed [11].
CULTIVATED MULTIPOTENT 
MESENCHYMAL STROMAL CELLS
Identifying MScs and  analyzing  them directly in tis-
sues are very complicated tasks. Hence, most conclu-
sions relating to the biological properties of MScs are 
made on the basis of a study of  stromal cell populations 
isolated from various tissues; these stromal cells possess 
the ability to attach culture plastic and to differentiate 
in osteogenic, adipogenic, and chondrogenic directions 
in vitro [12]. Despite the fact that, by their ability to re-
new and differentiate in various directions, these cells 
form a rather heterogenic population [13], they are also 
referred to as MScs. the International Society for cel-
lular therapy (ISct, Vancouver, canada) has suggest-
ed using the term “multipotent mesenchymal stromal 
cell” (MMSc) in order to separate such cultivated cells 
from MScs in situ. According to the minimal criteria 
developed by the ISct, MMScs should have the ability 
to attach to plastic during cultivation in ambient condi-
tions, to express cD105, cD73, and cD90 marker anti-
gens on the surface, but they should not contain cD45, 
cD34, cD14 or cD11b, cD79α or cD19, and HLA-Dr, 
and they also should differentiate into osteoblasts, ad-
ipocytes, and chondroblasts in vitro [14]. At present,   
bone marrow and adipose tissues are considered to be 
the most promising sources of MMScs for use in the 
study of the biological properties of these cells and for 
their application in regenerative medicine. However, 
multipotent mesenchymal stromal cells have  also been 
isolated from other tissues, including skin, thymus, 
spleen, and endometrium [15]. It should be taken into 
account that MMScs isolated from different postnatal 
and embryonal tissues differ from each other in the fol-
lowing ways: by their ability to form colonies, by gene 
expression, and by their differentiation potential even 
if they had been cultivated under the same conditions 
[9, 15–18]. From these distinctions,  questions as to the   
extent to which the cells (selected based on their ability 
to attach to plastic and grow in ambient conditions of 
cultivation) are biologically equivalent to one another 
and whether or not these differences are the result of 
various biological functions of MScs in the correspond-
ing tissues  arise [12].
MULTIPOTENCY OF MMSCs
In addition to their ability to differentiate into osteob-
lasts, chondroblasts, and adipocytes in vitro [7], MMScs 
give rise to bone or cartilage after ectopic transplanta-
tion in vivo in animal models [3], as well as mediate the 
regeneration of bone tissue following injuries [11] and 
when genetic defects occur in osteogenesis  (osteogen-
esis imperfecta) [19]. Moreover, many investigations 
have shown that MMScs have the ability to differen-
tiate into a variety of cells having mesodermal, ecto-
dermal, and endodermal origins, including endothe-
lial cells [20], cardiac myocytes [21], hepatocytes [22], 
and neural cells [23]. A number of authors, however, 
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conceding the ability of MMScs to differentiate into 
osteoblasts, chondroblasts and adipocytes, continue to 
doubt  the ability of MMScs to differentiate into cells 
of other germ layers (endodermal and ectodermal) both 
in vitro and in vivo [12]. It has thus been shown that, 
post transplantation, bone marrow-derived MMScs 
can integrate into the tissues of a recipient by  fusion 
with resident cells [24] rather than through differentia-
tion into the cells typical of the particular tissue.
the differences in the assessment of the differentia-
tion potential  of cultivated MMScs can be explained 
by the dissimilar quantitative and qualitative compo-
sitions of progenitor cells in tissues from which they 
were obtained. Firstly, the isolated population of MScs 
is heterogenic and includes cells with differing mor-
phologies and cells exhibiting different proliferative 
and differentiation abilities in vitro and in vivo [25, 26]. 
Furthermore, the multipotency of MMScs could disap-
pear as they are being cultivated [25]. thus, the clones 
of umbilical-cord-derived MMScs, which differ from 
each other by their degree of self-renewal and by their 
differentiation potential in vitro, produce daughter 
clones that gradually lose their multipotency [25].
Secondly, it is possible that the newly isolated popu-
lations of MMScs can contain progenitor cells already 
committed in various differentiation directions. thus, 
according to the results of a cytometric analysis, adi-
pose tissue contains at least five progenitor cells differ-
ing in the expression of marker antigens: sub-endothe-
lial progenitor cells (cD146+, cD140b+, nG2+, α-actin-, 
cD31-, cD90-/+, and cD34-), supra-adventitional pro-
genitor cells (nG2+, cD90+, cD34+, cD146-, cD31-, 
and α-actin-), and transient progenitor cells (cD146+, 
cD34+, nG2+, cD90+, and cD31-), preadipocyte pro-
genitor (cD34+, cD184+, and cD31-), and endothelial 
progenitor cells (cD34+, cD146+, cD133+, cD202b+, 
cD309+, cD31-, cD90-/+, and α-actin-) [26]. In this au-
thor’s opinion, the fact outlined above explains the 
frequent presence of endothelial islands (which disap-
pear with cultivation) in a primary culture of MMScs 
and explains the spherical shape of the colonies that 
are formed by small, and rapidly dividing rounded cells 
and large, very slowly dividing spread cells [27].
thirdly, along with MScs, all tissues contain minor 
subpopulations of pluripotent cells that have a wider 
spectrum of differentiation abilities, such as minute 
embryonic-like (VSeL) cells [28], multipotent adult pro-
genitor cells (MAPcs) [29], and multilineage differenti-
ating stress-enduring (MuSe) cells [30]. Our data indi-
cate the presence of very small embryonic-like cells in 
a newly isolated population of MMScs; but the contri-
bution of these minor populations to the differentiation 
potential of the MMSc culture remains unclear, since it 
is unknown whether they retain their growth and dif-
ferentiation ability under cultivation conditions.
the disagreement in the analysis of the multipotency 
of MMScs can also be attributed to the use of different 
techniques for isolation and cultivation, as well as the 
various assessment criteria of differentiation.
MMSCs AND TISSUE GROWTH
transplantation of MMScs stimulates the regeneration 
of tissues, including bone, skeletal muscles, myocar-
dium, skin, liver, and peripheral nerves. According to 
our data, this  occurs owing to both the integration of 
transplanted MMScs into the recipient’s tissues and 
the secretory activity of these cells [31]. It was demon-
strated that transplanted MScs integrate  the endothe-
lial lining of growing capillaries and  the periendothelial 
space of newly formed blood vessels, thereby stabiliz-
ing them.
MScs are an important source of growth factors and 
cytokines, which participate in the regulation of tis-
sue regeneration. thus, MScs produce factors in the 
bone marrow that are necessary for the self-sustenance 
of  hematopoietic stem cells and keep them in a niche; 
we can refer to such factors as SDF-1α (the stromal 
factor-1α), ScF (stem cell factor), angiopoietin -1, and 
interleukin-7 [32]. It was established in our labora-
tory that MScs produce angiogenic and neurotrophic 
growth factors, including VeGF (vascular endothelial 
growth factor), bFGF (basic fibroblast growth factor), 
HGF (hepatocyte growth factor), angiopoietin, nGF 
(nerve growth factor), BDnF (brain-derived neuro-
trophic factor), and GDnF (glial cell line-derived neu-
rotrophic factor) [33, 34]. the angiogenic growth fac-
tors produced by MMScs in the transplantation region 
stimulate the division of endothelial cells, their migra-
tion, and the formation of blood vessels. In addition, 
the factors produced by MMScs promote the mobiliza-
tion of endothelial progenitors from the bone marrow, 
which participate in the formation of new blood ves-
sels [34, 35]. Simultaneously, the neurotrophic factors 
produced by MMScs stimulate both the growth and 
renewal of nerve endings [33]. thus, MScs can mediate 
the coordinated regulation of the growth of blood ves-
sels and nerves during regeneration and remodeling of 
tissues (Fig. 2).
According to our data, MMScs produce the following 
factors necessary for the functional maturation of blood 
vessels and their stabilization: bFGF, PDGF-BB (plate-
let-derived growth factor BB), and tGF-β (transform-
ing growth factor beta) [18, 34, 36]. PDGF-BB initiates 
branching to them of growing blood vessels and migra-
tion of pericytes, smooth muscular cells, and mesenchy-
mal cells; while tGF-β stimulates the differentiation of 
the smooth muscular cells and the production of the ex-
tracellular matrix components of the vascular wall [37].reVIeWS
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the amount of growth factors and cytokines pro-
duced in MScs significantly increases when organs 
and tissues are damaged. Hypoxia causes coordinat-
ed changes in the expression of genes in MMScs: the 
level of mrnA for the proangiogenic factors, such as 
VeGF, PIGF, HGF, bFGF, PDGF-BB, and tGF-β, in-
creases by a factor of 2–4; and the mrnA level for an-
ti-angiogenic factors, such as PAI-a, angiostatin, and 
thrombospondin, decreases  more than twofold  [34]. 
Furthermore, MMScs secrete neurotrophic factors, in-
cluding nGF, BDnF, and GDnF, which are responsible 
for the stimulation of growth and regeneration of the 
nerve filaments that are a result of the transplantation 
of MMScs [33, 38].
the secretory activity of MMScs also affects their 
immunomodulating properties. In several animal mod-
els, it was revealed that the injection of cultivated 
MMScs causes immunosuppression in vivo [39]. the 
immunosuppressive effect of MMScs is based on the 
suppression of the function of  immune cells by means 
of the following: through the activation of t cells, via 
the differentiation of dendrite cells, through the prolif-
eration of B cells, and by means of the cytolytic activity 
of natural killers. the immunosuppressive properties 
of these cells are mediated by the secretion of soluble 
factors, including interleukin-10, prostaglandin-e2, 
nitric oxide, tGF-β1, galectin-1 and galectin-3, as well 
as by the indirect intercellular contact of MMScs with 
immune cells [40]. Moreover, MMScs can promote the 
differentiation of naive t helpers into regulatory t cells 
and the migration of mature regulatory t cells [39, 40]. 
the colocalization of bone marrow-derived MScs with 
dendrite cells and circulatory B cells in the perisinusoid 
space [41, 42] enables the reasonable assumption that 
MScs are involved in the regulation of the functional 
activity and maturation of immune cells.
MMSCs AND TUMOR GROWTH
tumor growth and angiogenesis are examples of  path-
ologic remodeling of tissues.  Mesenchymal cells are 
known to interact with tumor cells, both sustaining 
and inhibiting tumor growth in vitro and in vivo. It has 
thus been revealed that, in vitro, bone marrow-derived 
MMScs stimulate the proliferation of pancreatic cancer 
cells [43], while MMScs from the subcutaneous adipose 
tissue suppress the proliferation of primary leukemia 
cells [44]. In animal models, it was found that MMScs 
stimulate the retention and growth of tumor cells when 
they are injected in conjunction with melanoma cells 
[45–47], breast cancer [48], prostate cancer [49], as well 
as bowel cancer [50, 51]. In addition, they also increase 
the probability of metastasis formation [52]. In all likeli-
hood, the stimulating effect of MMScs occurs owing to 
the secretion of chemokines (ccL5, SDF-1α) and ag-
iogenic growth factors (VeGF) and  to their anti-apop-
totic influence on tumor cells. In addition, MMScs have 
the ability to migrate to tumor tissue and participate in 
the formation of its stroma. thus, in tumors, MMScs 
differentiate into fibroblasts, endothelial cells, and 
pericytes, thereby stimulating tumor growth [46, 53]. 
MMScs are also capable of secreting cytokines, growth 
factors, and angiogenic factors [34, 43]; this stimulates 
tumor growth through increasing their vasculariza-
tion.
It should be noted, however, that in these and other 
models, MMScs can actually suppress tumor growth 
under particular conditions. there are several underly-
ing processes for this MMScs effect, such as the stimu-
lation of the inflammatory reaction in the recipient’s 
body in the case of colorectal cancer [50]; the activa-
tion of the Akt and Wnt signaling pathways in Kaposi’s 
sarcoma cells, hepatoma cells, and breast cancer cells 
[54–56]; cell cycle arrest in G1-phase occurring in pan-
creatic cancer cells, hepatoma cells, and lymphoma cells 
[44, 57]; induction of apoptosis in tumor and endothelial 
cells in hepatoma and non-Hodgkin’s lymphoma [44, 
58]; and the suppression of angiogenesis in melanoma of 
B16F10 mice [57]. the systematic injection of MMScs   
to experimental animals suffering from induced ma-
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Fig. 2. Stimulation of growth of blood vessels and axons 
under the action of MSCs. Adipose tissue-derived MSCs 
were transplanted as subcutaneous matrigel implants in 
syngeneic mice. Blood vessel (upper panels) and axon 
(lower panels) densities were evaluated by immunofluo-
rescent staining of frozen sections with antibodies against 
the markers of endothelium (CD31, green fluorescence) 
and pericytes (NG2, red fluorescence), or axonal cy-
toskeleton protein (NF200, red fluorescence). Cell nuclei 
are counterstained by DAPI. Short arrows indicate mature 
blood vessels, long arrows indicate axons. The diagrams 
represent the results of morphometry for the total length 
of blood vessels (upper diagram) and axons (lower dia-
gram) [33, 34].34 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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ture mancreatic cancer led to the apoptosis of tumor 
cells in vitro and  to the suppression of tumor growth 
in vivo [57].
the data obtained during the study of the effect of 
MScs on tumor growth indicate that the activation of 
MScs, their directed migration, and their differentia-
tion into the cells of connective tissue and blood vessels, 
as well as their interaction with immune cells, are im-
portant processes in oncogenesis.
IDENTIFICATION OF MSCs in vivo 
the distribution of MScs in tissues has remained un-
clear for a considerable period of time [13, 32], since 
the fraction of such cells in tissues is rather small, and 
the unique immunophenotype distinguishing them 
from other cells had not been determined. new mark-
er antigens of MScs were determined via the assess-
ment of the ability of cells, which were isolated from 
tissues in accordance with their ability to express par-
ticular proteins, for self-renewal and differentiation 
in vivo.
It was recently revealed that in the bone marrow 
of mice, the following cells satisfy the criteria for 
MScs: cells expressing Sca-1 (stem cell antigen-1) 
and PDGFrα (platelet-derived growth factor receptor 
α). these cells formed bone tissue and the functional 
stroma for HScs during their heterotopic transplanta-
tion under the skin and osteoblasts, reticular cells, and 
adipocytes in the bone marrow after their systematic 
transplantation to an exposed recipient [13]. It was es-
tablished  using the same approach, that nestin can 
also be a marker of bone marrow-derived MScs [32]; 
this conclusion was drawn since the cells expressing 
nestin possessed the ability to self-renew in vitro and 
in vivo,  differentiated into osteoblasts and chondro-
cytes in the bone marrow in vivo, and formed a he-
matopoietic microenvironment when  transplanted 
under the skin [59].
By using new marker antigens (cD146, Sca-1, and 
PDGFrα), it was shown that, in situ, MScs accu-
mulate in the immediate vicinity of blood vessels; in 
particular in the adventitia of the arteries supplying 
blood to the bone marrow. Moreover, the cells, which 
were isolated in accordance with their perivascular 
localization and the ability to express  pericyte mark-
ers (nG2 [chondroitin sulfate proteoglycan], cD146, 
and PDGFrβ) from various human organs and tissues, 
including the fetal and postnatal skin, the pancreas, 
the heart, the lungs, the bone marrow, and placenta, 
had the ability to self-maintain and also possessed dif-
ferentiation potential and  expression profiles that are 
typical of MScs [60].
 It is now widely believed that the cells producing 
the marker antigens of MScs and  pericytes in vivo are 
found in close proximity to blood vessels, in adipose tis-
sue, and in dental pulp [61, 62].
Despite the similarities in the localization and ability 
to express surface markers, the ability to differentiate 
into osteoblasts, chondrocytes, adipocytes, myocytes, 
and smooth muscle cells in vitro and  form the foci of 
ectopic osteogenesis in vivo [60], the problem of the 
biological equivalence of MScs and pericytes remains 
unresolved.
It remains thus unclear whether MScs incorporate 
all of the functions of pericytes in vivo: e. g., the sta-
bilization of capillaries, phagocytosis, and the regu-
lation of the permeability and tonus of blood vessels, 
including those functions that are controlled through 
the reception of signals from the sympathetic nervous 
system [63]. the periendothelial space of blood vessels 
in all likelihood contains heterogenic cell populations. 
Apparently, only a portion of pericytes can belong to 
MScs in vivo. the perivascular localization is a typical 
feature of not only MScs; it has been noted in resident 
stem cells (or progenitor cells), HScs, preadipocytes, 
and stem cells in the skeletal muscles of the bone mar-
row, in adipose tissues, and skeletal muscles [64–67]. 
the presence of MScs in the periendothelial space in-
dicates that endothelium is an important component 
of the MSc niche, which can regulate their functional 
activity.
MSCs ARE  COMPONENTS OF THE 
TISSUE-SPECIFIC CELL NICHE
Studying the functions of MScs in various tissues 
has become  a topical research task. In the bone mar-
row, MScs provide not only the renewal of stroma, 
but they are also an important regulator of hematosis 
and the functions of HScs. HScs in the bone marrow 
have a particular microenvironment (niches), which is 
comprised of non-hematopoietic cells, soluble factors 
and proteins of the territorial matrix, which regulate 
the process of hemopoiesis [69]. At the beginning of 
studies  of the role of MScs, these cells in vivo were 
found to be a source of osteoblasts, adipocytes, and 
reticular cells; altogether, these cells make up the 
niche for HScs, which participate in hemopoiesis [3]. 
In addition, MScs are the first to populate the sites of 
fetal hemopoiesis, transmitting the regulatory signals 
causing the migration of HScs to those sites [70]. cul-
tivated bone marrow-derived MMScs are also capable 
of maintaining the survival and proliferation of HScs 
ex vivo [70].
Osteoblasts are necessary components of the he-
matopoietic microenvironment [71–72]. the number 
of osteoblasts in the bone marrow positively corre-
lates with the number of HScs [73]; i. e., around 14% 
of HScs are located in the immediate vicinity of the reVIeWS
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osteoblast-lined endosteum [65]. the ability of oste-
oblasts to regulate the self-maintenance and activa-
tion of HScs has not yet been confirmed unequivo-
cally. However, data  showing that these cells regulate 
the differentiation of HScs into granulocytes and B 
lymphocytes through the secretion of soluble growth 
factors and cytokines, such as LIF-1 (leukemia inhibi-
tory factor-1), GM-cSF (granulocyte macrophage 
colony-stimulating factor), SDF-1, and interleukin-6 
has been obtained in vitro [69]. Along with osteoblasts, 
the stroma of the bone marrow contains adipocytes, 
which  also originate from MScs. It is of interest that 
adipocytes function in the bone marrow as negative 
regulators of hemopoiesis, acting through a mecha-
nism that is still unknown [74]. consequently, bone-
marrow MScs  play the role of a source for two types 
of cells (osteoblasts and adipocytes), which exhibit 
antagonist activity in the regulation of HScs. It re-
mains unclear what is the deciding factor concerning 
the direction in which MScs differentiate, and how 
the balance between the production of osteoblasts and 
adipocytes would affect hemopoiesis. [12].
MScs can also regulate the hemopoietic microenvi-
ronment by arranging a vasculature in the bone mar-
row; the latter is a necessary structural and functional 
component of HSc niches [69]. the existence of dual 
stem-cell niches containing two types of stem cells, 
HScs and MScs, which directly interact in the perivas-
cular spaces of the brain marrow, was confirmed in two 
independent studies. In particular, it was established 
that the majority of HScs are located at a distance of 
below 30 µm (~5 diameters of a HSc) from the reticu-
lar cells which produce a large amount of SDF-1α and 
nestin [13, 32]. As was mentioned above, these cells are 
MScs or their closest descendants, since they are ca-
pable of both self-maintenance and differentiation in 
the osteogenic and adipogenic directions both in vitro 
and in vivo.
nestin-positive MScs express factors are required 
to keep HScs in their niche and for them to self-main-
tain; accordingly, their number should be 50–700 times 
higher than that of the other stromal cells of the bone 
marrow. In addition, nestin-positive MScs maintain 
the growth of HSc colonies in vitro, and their removal 
causes a drastic fall in the amount of HScs in vivo.
the distinctive features of nestin-expressing MScs 
from the bone marrow are the expression of β3-
adrenoreceptors and their ability to respond to  signals 
from the nervous system. the agonists of β3- and β2-
adrenoreceptors induce suppression in the expression 
of SDF-1α, ScF, angiopoetin-1, and interleukin-7 by 
nestin-exressing MScs; the latter, in  turn, leads to the 
mobilization of HScs. thus, hemopoiesis is regulated by 
the nervous system in this manner.
It has been well-known since the time of Virchow 
that pericytes with  periendothelial localization can be 
targets for axon endings, thereby playing a key role in 
the transmission of signals from the nervous system to 
the vascular system [75]. As was noted above,  part of 
pericytes belong to MScs. therefore, the MSc function 
of connecting the compartment of HScs and the nerv-
ous system is in good agreement with their perivascular 
localization (Fig. 3).
Bone-marrow-derived MScs are also targets for in-
nate immunity cells, such as macrophages. In contrast 
to the nervous system stimulating mobilization, bone-
marrow-derived macrophages promote the retention 
of HScs in the niche [76].
It remains unclear whether  MScs from other tissues 
are part of the niches for tissue-specific resident stem 
cells, and if they mediate the action of the nervous sys-
tem in these niches. thus, MScs isolated from myocar-
dium were found to be capable of stimulating the sur-
vival and proliferation of cardiac stem cells in vitro [77]; 
however, the questions of whether and how these cells 
interact with tissue-specific stem cells in vivo  remains 
unanswered [78]. In both the small intestine and skin, 
the populations of MScs responsible for the renewal of 
these tissues after injury were identified. However, the 
degree of importance of their interaction with tissue-
specific stem cells for the processes of tissue renewal 
has yet to be studied. It is at least known, however, that 
bone-marrow MScs  are a necessary component of the 
perivascular niche for the tissue-specific resident stem 
cells (in this case HScs) which enable integration be-
tween  signals from the nervous and immune systems 
and the peripheral blood flow.
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Fig. 3. Hypothetic scheme showing the interaction of 
MSCs with axons, endothelial cells, leukocytes, and 
tissue-specific stem cells (see details in the text).36 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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CONCLUSIONS
the results presented in this review allow us to suggest 
that there are two types of MScs in the body: bone-
marrow-derived MScs circulating in the blood, which 
participate in tissue repair upon injury, and resident 
MScs, which are located in the perivascular region of 
all organs and tissues of the body and regulate physi-
ological tissue renewal and the maintenance of tissue 
homeostasis. MScs are  important participants in the 
processes of tissue renewal and regeneration. Firstly, 
they  regulate the self-maintenance and differentiation 
of tissue-specific stem cells. Secondly, MScs stimulate   
growth, as well as stabilize blood vessels and nerves in 
the processes of tissue repair. thirdly, the interaction 
between MScs and lymphocytes, endothelial cells and 
axons facilitates the integration of the neurohumoral 
signals which regulate tissue renewal and repair. 
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